Marshall Wace LLP Buys 32,015 Shares of InfuSystem Holdings, Inc. (NYSE:INFU)

Marshall Wace LLP boosted its stake in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 150.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,315 shares of the company’s stock after buying an additional 32,015 shares during the period. Marshall Wace LLP owned approximately 0.25% of InfuSystem worth $451,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Barclays PLC increased its position in shares of InfuSystem by 300.5% during the third quarter. Barclays PLC now owns 28,597 shares of the company’s stock valued at $192,000 after acquiring an additional 21,457 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of InfuSystem by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock worth $2,925,000 after purchasing an additional 7,550 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of InfuSystem by 74.1% in the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock worth $104,000 after purchasing an additional 6,623 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of InfuSystem by 25.9% during the fourth quarter. First Eagle Investment Management LLC now owns 908,371 shares of the company’s stock valued at $7,676,000 after purchasing an additional 186,668 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of InfuSystem during the fourth quarter valued at $90,000. Hedge funds and other institutional investors own 71.13% of the company’s stock.

Wall Street Analysts Forecast Growth

INFU has been the subject of a number of recent analyst reports. Sidoti raised InfuSystem to a “strong-buy” rating in a research report on Tuesday, March 18th. StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 14th.

InfuSystem Trading Up 2.1 %

InfuSystem stock opened at $4.85 on Friday. InfuSystem Holdings, Inc. has a 52-week low of $4.61 and a 52-week high of $9.97. The company has a market cap of $101.93 million, a P/E ratio of 80.85 and a beta of 1.90. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $5.53 and a two-hundred day simple moving average of $7.21.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.